Abstract
PurposeThe aim of this study is to address the safety and effectiveness of a second continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) treatment by comparing its outcome against a first CW-TSCPC treatment in the same patients with refractory glaucoma.MethodsTwenty-one eyes with either primary or secondary glaucoma received a second CW-TSCPC laser session ≥ 3 months after the first treatment. Intraocular pressure (IOP), best-corrected visual acuity (BCVA), and number of topical or oral ophthalmic pressure-reducing medications were registered at every time point up to the last follow-up at 3 months. A complete slit-lamp examination was conducted to record for complications or other abnormal ocular findings. Success was defined as IOP between 6 and 21 mmHg and > 20% reduction in IOP with or without anti-glaucoma medications.ResultsAt 3 months follow-up of the first CW-TSCPC treatment, a 24.8% decrease in IOP was observed, whereas a 45.6% IOP decrease was observed 3 months post the second CW-TSCPC treatment. Visual acuity did not decrease, and no major complications were observed post either treatment within the follow-up period. Time to failure was 79.5 ± 24.6 and 77.1 ± 29.4, respectively (P = 0.955). No serious complications were observed.ConclusionA second CW-TSCPC treatment proved to be a safe and effective treatment option when the first CW-TSCPC treatment was insufficient in maintaining the desired IOP level for a prolonged time (mean time between both sessions 6.4 ± 8.0 months).
Highlights
Glaucoma is a chronic, progressive optic neuropathy with a multi-factorial etiology [1,2,3,4,5]
Glaucoma is associated with a pathological increase of intraocular pressure (IOP) (> 21 mmHg), 1 3 Vol.: (0123456789)
Patients selected for the study had either primary or secondary glaucoma and were diagnosed with moderate to advanced glaucoma
Summary
Progressive optic neuropathy with a multi-factorial etiology [1,2,3,4,5]. It is the leading cause of irreversible blindness worldwide [6,7,8]. An irreversible damage of the optic nerve and a progressive loss of nerve fibers causes vision loss [9,10,11]. An appropriate and timely therapy can effectively prevent progressive nerve damage, loss of visual field, and blindness [12,13,14,15]. There are several ways of achieving IOP reduction: (1) medical treatment (mostly topical eye drops), (2) surgical procedures (incisional surgeries and minimally invasive glaucoma surgery (MIGS) procedures), or (3) lasers (i.e., laser trabeculoplasty, endocyclophotocoagulation, cyclophotocoagulation) [18,19,20,21]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
